Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.
Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.